1		Louisiana Administrative Code				
2 3 4		Title 46 – Professional and Occupational Standards				
5		Part LIII: Pharmacists				
6 7	Cha	Chapter 24. Limited Service Providers				
8 9	Suł	ocha	apter E. Marijuana Pharmacy			
10 11	§24	40.	Preamble; Warning; Consultation Suggested			
12	A.	Pur	rsuant to Act 261 of the Regular Session of the 2015 Louisiana Legislature as well as the subsequent			
13			endments found in Act 96 of the Regular Session of the 2016 Louisiana Legislature, the Board of Pharmacy			
14			s directed to:			
15		1.				
16		2.	Adopt rules relating to the dispensing of recommended marijuana for therapeutic use, with such rules to			
17			include, at a minimum, the following:			
18			a. – d			
19			e. Standards, procedures, and protocols to ensure all recommended therapeutic marijuana dispensed,			
20			with the exception of raw or crude marijuana product, is consistently pharmaceutical grade;			
21			f. – k			
22			1. limitations on dispensing of raw or crude marijuana.			
23	B. –	C				
24						
25	AUT	THOR	RITY NOTE: Promulgated in accordance with R.S. 40:1046.			
26	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1538 (August 2017), amended LR					
27			* * *			
28	§24	43.	Marijuana Products			
29	A.	Exc	clusive Source.			
30		1.	The exclusive source of marijuana products shall be the producers licensed for that activity by the			
31			Department of Agriculture and Forestry (LDAF).			
32		2.	That Licensed producers shall prepare pharmaceutical grade marijuana products as well as raw marijuana			
33			products for distribution to the marijuana pharmacies licensed by the board.			
34		3.				
35	B.	Lab	poratory Testing			
36		1.				
37		2.	A producer shall make available each such batch at the production facility for testing by a laboratory			
38			approved by LDAF. The laboratory employee shall select a random sample from each batch.			

Regulatory Proposal 2021-D ~ Raw Marijuana Products

39	a. Medical marijuana concentrate shall not be used to produce any final product until it has passed all	
40	analysis limits for:	
41	i. – v	
42	b. Product shall not be released for delivery to a marijuana pharmacy for sale or consumption until it	
43	has passed all <u>concentrate</u> analysis limits for:	
44	i. – iii	
45	c. Final products not produced from concentrate, e.g., dried and cured flower) shall not be released for	•
46	delivery to a marijuana pharmacy for sale or consumption until it has passed all analysis limits for:	
47	i. active ingredient analysis for characterization of potency;	
48	ii. pesticide active ingredients, including but not limited to the most recent list of targeted	
49	pesticides published by LDAF;	
50	iii. heavy metals;	
51	iv. mycotoxins;	
52	v. microbiological contaminants; and	
53	vi. homogeneity.	
54	e d. LDAF personnel may select a random sample at any point in the process for the purpose of analysis	
55	for anything the LDAF deems necessary.	
56	d e. Samples shall be secured in a manner approved by LDAF at all times when not in immediate use for	r
57	the analyses being conducted.	
58	3	
59	4. Testing Specifications	
60	a. – c.iv	
61	d. With respect to the pesticide chemical residue test, a marijuana sample shall be deemed to have	
62	passed if it satisfies the most stringent acceptable standard for a pesticide chemical residue in any	
63	food item as set forth in Subpart C of the United States Environmental Protection Agency's	
64	"Tolerances and Exemptions for Pesticide Chemical Residues in Food" as found in 40 CFR 180 or i	ts
65	successor does not contain any residues not appearing on LDAF's approved list and any approved	
66	residues present are less than the limits allowed by LDAF.	
67	e	
68	f. With respect to the test for homogeneity, a marijuana sample shall be deemed passed if each aliquot	
69	tested is within plus or minus 15 percent of the total aliquots average finding for potency for each	
70	labeled active ingredient. Any solid product will be considered not homogenous to have failed if 10)
71	percent of the sample product contains more than 20 percent of the total active ingredient.	
72	g. Every sample shall undergo an active ingredient analysis or potency analysis.	
73	i. – i.(d)	
74	ii. For product samples, the potency test is to establish the active ingredient composition for	

Regulatory Proposal 2021-D ~ Raw Marijuana Products

75	verification of labeling to ensure accurate dosing. The maximum variance permitted is 15 percent
76	from the labeled amount. For example, a product labeled as containing 10 milligrams of
77	tetrahydrocannabinol (THC) shall contain no less than 8.5 milligrams THC and no more than 11.5
78	milligrams THC. For final products containing THCA, the total THC determined shall also be
79	within the variance allowed for the THC as labeled.
80	B.5. – B.8
81	C. Product Dosage Forms.
82	1. The producer shall limit their production of pharmaceutical grade marijuana products to the following
83	dosage forms:
84	a. – c
85	d. Gelatin-based or pectin-based chewables;
86	e. – h
87	i. Bulk raw product.
88	2. The producer may produce other products from raw or crude marijuana, including dried flower, buds and
89	other plant material, intended for the following methods of administration:
90	a. <u>Combustible forms for inhalation, including but not limited to pre-rolls; and</u>
91	b. Edible forms for ingestion.
92	2 <u>3</u> . No marijuana product shall:
93	a. include alcoholic liquor, dietary supplements, or any drug, except for pharmaceutical grade
94	marijuana. For purposes of this provision, alcoholic liquor does not include any liquid or solid
95	containing less than 0.5 percent of alcohol by volume, or ethanol-based tinctures.
96	b. be manufactured or sold as a beverage.
97	e <u>b</u> . be manufactured or sold in a form or with a design that:
98	i. – iv
99	d c. have had pesticide chemicals or organic solvents used during the production or manufacturing
100	process other than those which may be approved by the commissioner of LDAF.
101	3 4. Any marijuana product not in compliance with the provisions of this Paragraph Section shall be deemed
102	adulterated.
103	D. – E.4.f
104	
105	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.
106	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1540 (August 2017), amended LR
107	45:1473 (October 2019), LR 46:568 (April 2020), amended LR 46:1227 (September 2020), LR 47:590 (May 2021), <u>LR</u> * * *
108	
109	§2453. Security Requirements for Marijuana Pharmacies

110 A. A marijuana pharmacy shall:

111	1. – 3
112	4. keep all approved safes and vaults securely locked and protected from entry, except for the actual time
113	required to remove or replace marijuana, provided that during hours of operation the pharmacist-in-charge
114	may authorize the placement of a limited quantity of dispensing stock outside such safes or vaults but
115	within the secure prescription department.
116	A.5. – H
117	
118	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.
119	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1548 (August 2017), amended LR
120	* * *
121	§2457. Standards of Practice
122	A. – D.5
123	E. Professional Practice Standards
124	1. Recommendation / opinion / referral (hereinafter "request") for Therapeutic Marijuana
125	1.a. – 1.a.ii
126	b. The request shall disclose the following information at a minimum:
127	i. – iii
128	iv. treatment type of marijuana product requested.
129	v. – vii
130	c. Requests for marijuana products shall expire one year after the date of issue, unless a shorter period
131	of time is indicated by the physician. A pharmacist may dispense marijuana product on multiple
132	occasions as indicated by the physician and as needed by the patient until the request expires;
133	however, the pharmacist shall not dispense more than a 90 day supply of marijuana product at one
134	time nor more than a one year supply of marijuana product pursuant to a single request. A
135	pharmacist shall not dispense marijuana product pursuant to an expired request.
136	d. Requests for raw or crude marijuana products intended for persons under 21 years of age shall
137	specifically indicate a recommendation for raw or crude forms of marijuana for such persons.
138	d e. A marijuana pharmacy shall transfer an unexpired request for marijuana product to another
139	marijuana pharmacy when requested by the patient or his caregiver.
140	2. Dispensing Marijuana Products
141	<u>a</u> . Prior to dispensing any marijuana product to a patient, the pharmacist shall review the patient's
142	records in the state prescription monitoring program. The pharmacist shall resolve any concerns
143	identified in that review by consultation with the recommending physician.
144	b. Dispensing Limitations
145	i. A pharmacist shall not dispense more than two and one-half ounces, or 71 grams, of raw or
146	crude marijuana every 14 days to any person.

Regulatory Proposal 2021-D ~ Raw Marijuana Products

147	ii. Subject to the above limitation on dispensing raw or crude marijuana products, a pharmacist
148	may dispense marijuana products on multiple occasions as indicated by the physician and
149	needed by the patient until the request expires; however, the pharmacist shall not dispense more
150	than a 90-day supply of marijuana product at one time nor more than a one-year supply
151	pursuant to a single request.

- 152 E.3. E.6.e.iv. ...
- 153
- 154 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.
- 155 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1550 (August 2017), amended LR
- 156 45:1473 (October 2019), LR 47:246 (February 2021), LR 47:1111 (August 2021), <u>LR</u>
- 157